WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

This group comprises all products acting on the alimentary tract and metabolism which cannot be classified in the preceding groups. V03 - All other therapeutic products, should also be considered.
Nutrients are classified in V06 - General nutrients.


A16AA Amino acids and derivatives

Agents used in various metabolic deficiency states are classified here, when this is considered to be the main indication e.g. levocarnitine. Tryptophan and oxitriptan are classified in N06A.
Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in this group.
Glutamine for treatment of sickle cell disease is classified here.

The DDD of levocarnitine is based on treatment of primary carnitine deficiency.

A16AB Enzymes

This group includes gene therapy products resulting in the expression of specific enzymes.

A16AX Various alimentary tract and metabolism products

Thioctic acid is classified in this group.
This group includes gene therapy products resulting in the expression of specific proteins.

The DDD for zinc acetate is expressed as the amount of zinc (Zn).
The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.
The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.
The DDD for miglustat is based on the treatment of Gauchers disease.

Last updated: 2024-01-26